Cyclacel Pharmaceuticals, Inc.
CYCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$35 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $4 |
| Gross Profit | $0 | -$1 | $0 | -$39 |
| % Margin | 21% | – | – | 111.4% |
| R&D Expenses | $0 | $0 | $822 | $879 |
| G&A Expenses | $1 | $1 | $4,214 | $948 |
| SG&A Expenses | $1 | $1 | $4,214 | $948 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,316 | $0 | $1 |
| Operating Expenses | $1 | $1,317 | $5,036 | $1,828 |
| Operating Income | -$1 | -$1,317 | -$5,036 | -$1,828 |
| % Margin | -1,224.7% | – | – | 5,222.9% |
| Other Income/Exp. Net | $0 | $1 | $4,955 | -$30 |
| Pre-Tax Income | -$1 | -$1,316 | -$81 | -$1,858 |
| Tax Expense | $0 | $2 | $0 | $1,194 |
| Net Income | -$1 | -$1,318 | -$81 | -$3,052 |
| % Margin | -1,219.8% | – | – | 8,720% |
| EPS | -1.31 | -0.84 | -6.25 | -0.35 |
| % Growth | -56% | 86.6% | -1,685.7% | – |
| EPS Diluted | -1.31 | -0.84 | -6.25 | -0.35 |
| Weighted Avg Shares Out | 1,912 | 1,584 | 13 | 8,665 |
| Weighted Avg Shares Out Dil | 1,912 | 1,584 | 13 | 8,665 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $6 | $30 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $2 | $1 |
| EBITDA | -$1 | -$1,315 | -$5,035 | -$1,885 |
| % Margin | -1,208.6% | – | – | 5,385.7% |